Avalanche Biotechnologies (AAVL) Priced

Early-stage biotech developing a gene therapy for wet AMD.

Health Care - Biotechnology

IPO Performance
Latest Trade $4.14 0.00 (0.0%)
First Day Return 64.6%
Return from IPO -75.6%
 
Avalanche Biotechnologies IPO News more
  • .
IPO Data
IPO File Date 06/30/2014
Offer Price $17.00
Price Range $16.00 - $17.00
Offer Shares (mm) 6.0
Deal Size ($mm) 102
 
IPO Data
IPO Date 07/30/2014
Offer Price $17.00
Price Range $16.00 - $17.00
Offer Shares (mm) 6.0
Deal Size ($mm) $102
 
Underwriters
more
Business Overview
Early-stage biotech developing a gene therapy for wet AMD.
Early-stage biotech developing a gene therapy for wet AMD.
more
Company Data
Headquarters Menlo Park, CA
Founded 2006
Employees 14
Website www.avalanchebiotech.com
 

Performance vs. IPO Index (IPOUSA)